{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:09:40Z","timestamp":1787616580789,"version":"build-2736575974"},"reference-count":127,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Normal tension glaucoma (NTG) is defined as a subtype of primary open-angle glaucoma (POAG) in which the intraocular pressure (IOP) values are constantly within the statistically normal range without treatment and represents approximately the 30\u201340% of all glaucomatous cases. The pathophysiology of this condition is multifactorial and is still not completely well known. Several theories have been proposed to explain the onset and progression of this disease, which can be divided into IOP-dependent and IOP-independent factors, suggesting different therapeutic strategies. The current literature strongly supports the fundamental role of IOP in NTG. The gold standard treatment for NTG tends to be based on the lowering IOP even if \u201cstatistically normal\u201d. Numerous studies have shown, however, that the IOP reduction alone is not enough to slow down or stop the disease progression in all cases, suggesting that other IOP-independent risk factors may contribute to the NTG pathogenesis. In addition to IOP-lowering strategies, several different therapeutic approaches for NTG have been proposed, based on vaso-active, antioxidant, anti-inflammatory and\/or neuroprotective substances. To date, unfortunately, there are no standardized or proven treatment alternatives for NTG when compared to traditional IOP reduction treatment regimes. The efficacy of the IOP-independent strategies in decreasing the risk or treating NTG still remains inconclusive. The aim of this review is to highlight strategies reported in the current literature to treat NTG. The paper also describes the challenges in finding appropriate and pertinent treatments for this potentially vision-threatening disease. Further comprehension of NTG pathophysiology can help clinicians determine when to use IOP-lowering treatments alone and when to consider additional or alternatively individualized therapies focused on particular risk factors, on a case-by-case basis.<\/jats:p>","DOI":"10.3390\/ph16081172","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T10:15:48Z","timestamp":1692267348000},"page":"1172","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pharmaceutical Approaches to Normal Tension Glaucoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6566-1075","authenticated-orcid":false,"given":"Maria Letizia","family":"Salvetat","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Azienda Sanitaria Friuli Occidentale, 33170 Pordenone, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Azienda Sanitaria Friuli Occidentale, 33170 Pordenone, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopoldo","family":"Spadea","sequence":"additional","affiliation":[{"name":"Eye Clinic, Policlinico Umberto I, \u201cSapienza\u201d University of Rome, 00142 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salati","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-5545","authenticated-orcid":false,"given":"Marco","family":"Zeppieri","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","article-title":"Glaucoma","volume":"390","author":"Jonas","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.mcna.2021.01.004","article-title":"Glaucoma","volume":"105","author":"Kang","year":"2021","journal-title":"Med. Clin. N. Am."},{"key":"ref_3","unstructured":"(2021). European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br. J. Ophthalmol., 105, 1\u2013169."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/BF02720732","article-title":"Iridectomie bei Glaucom and ueber den glaucomatosen Pozess","volume":"3","year":"1857","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_5","unstructured":"Gosling, D., and Meyer, J.J. (2023). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","article-title":"American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary Open-Angle Glaucoma Preferred Practice Pattern\u00ae","volume":"128","author":"Gedde","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jcjo.2015.03.005","article-title":"Evaluation of primary open-angle glaucoma clinical practice guidelines","volume":"50","author":"Wu","year":"2015","journal-title":"Can. J. Ophthalmol."},{"key":"ref_8","unstructured":"Asia-Pacific Glaucoma Society (APGS) (2023, August 07). Amsterdam, The Netherlands: Kugler Publications, 3th Edition. Available online: https:\/\/www.apglaucomasociety.org\/Public\/Public\/Resources\/APGG.aspx."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","article-title":"Glaucoma Guideline Preparation Committee, Japan Glaucoma Society. The Japan Glaucoma Society guidelines for glaucoma 5th edition","volume":"67","author":"Kiuchi","year":"2023","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0161-6420(92)31774-9","article-title":"Prevalence of glaucoma. The Beaver Dam Eye Study","volume":"99","author":"Klein","year":"1992","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ajo.2018.10.017","article-title":"Prevalence of Normal-Tension Glaucoma in the Chinese Population: A Systematic Review and Meta-Analysis","volume":"199","author":"Zhao","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/08820539909056069","article-title":"Glaucomatous versus nonglaucomatous optic disc cupping: Clinical differentiation","volume":"14","author":"Greenfield","year":"1999","journal-title":"Semin. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/bjophthalmol-2018-312161","article-title":"Optic nerve head cupping in glaucomatous and non-glaucomatous optic neuropathy","volume":"103","author":"Fard","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/08820538.2021.1897855","article-title":"Glaucoma Mimickers: A major review of causes, diagnostic evaluation, and recommendations","volume":"36","author":"Senthil","year":"2021","journal-title":"Semin. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/iovs.62.10.15","article-title":"Comparison of Optic Nerve Head Microvasculature Between Normal-Tension Glaucoma and Nonarteritic Anterior Ischemic Optic Neuropathy","volume":"62","author":"Kim","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/EB.S272343","article-title":"Neuro-Ophthalmological Optic Nerve Cupping: An Overview","volume":"13","author":"Waisberg","year":"2021","journal-title":"Eye Brain"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"109405","DOI":"10.1016\/j.mehy.2019.109405","article-title":"Is \u201cnormal tension glaucoma\u201d glaucoma?","volume":"133","author":"Fan","year":"2019","journal-title":"Med. Hypotheses"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/jovr.jovr_35_18","article-title":"Intraocular Pressure Fluctuation: Is It Important?","volume":"13","author":"Kim","year":"2018","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/cxo.12620","article-title":"Effect of central corneal thickness on intraocular pressure and comparison of Topcon CT-80 non-contact tonometry with Goldmann applanation tonometry","volume":"101","author":"Mansoori","year":"2018","journal-title":"Clin. Exp. Optom."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1159\/000530291","article-title":"Corneal Biomechanical Properties of various types of glaucoma and their impact on measurement of intraocular pressure","volume":"66","author":"Zhang","year":"2023","journal-title":"Ophthalmic Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/ICU.0b013e3282f3919b","article-title":"Normal-tension glaucoma: Is it different from primary open-angle glaucoma?","volume":"19","author":"Shields","year":"2008","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02713683.2022.2068182","article-title":"Retinal Ganglion Cell Death in Glaucoma: Advances and Caveats","volume":"48","author":"Yang","year":"2023","journal-title":"Curr. Eye Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.survophthal.2018.08.005","article-title":"Intraocular pressure-independent management of normal tension glaucoma","volume":"64","author":"Adeghate","year":"2019","journal-title":"Surv. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.survophthal.2021.12.003","article-title":"A review of potential novel glaucoma therapeutic options independent of intraocular pressure","volume":"67","author":"Shalaby","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"108506","DOI":"10.1016\/j.exer.2021.108506","article-title":"Protection of retinal ganglion cells in glaucoma: Current status and future","volume":"205","author":"Shen","year":"2021","journal-title":"Exp. Eye Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/1673-5374.344831","article-title":"Regulatory mechanisms of retinal ganglion cell death in normal tension glaucoma and potential therapies","volume":"18","author":"Shen","year":"2023","journal-title":"Neural. Regen. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhao, W.J., Fan, C.L., Hu, X.M., Ban, X.X., Wan, H., He, Y., Zhang, Q., and Xiong, K. (2023). Regulated Cell Death of Retinal Ganglion Cells in Glaucoma: Molecular Insights and Therapeutic Potentials. Cell. Mol. Neurobiol., ahead of print.","DOI":"10.1007\/s10571-023-01373-1"},{"key":"ref_28","first-page":"741","article-title":"Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons","volume":"41","author":"Quigley","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.4103\/1673-5374.259600","article-title":"Normal tension glaucoma: From the brain to the eye or the inverse?","volume":"14","author":"Zhang","year":"2019","journal-title":"Neural. Regen. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41433-018-0042-2","article-title":"Normal tension glaucoma: Review of current understanding and mechanisms of the pathogenesis","volume":"32","author":"Killer","year":"2018","journal-title":"Eye Lond."},{"key":"ref_31","first-page":"563","article-title":"Normal-tension glaucoma: Pathogenesis and genetics","volume":"17","author":"Trivli","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/ceo.14043","article-title":"Normal-tension glaucoma: Current concepts and approaches\u2014A review","volume":"50","author":"Leung","year":"2022","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/IJG.0000000000002071","article-title":"Twenty-Four-Hour Intraocular Pressure Indicators Distinguish Normal Tension Glaucoma From Healthy Eyes Measured With a Contact Lens Sensor","volume":"31","author":"Tojo","year":"2022","journal-title":"J. Glaucoma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1167\/iovs.13-11792","article-title":"Intraocular pressure change over a habitual 24-hour period after changing posture or drinking water and related factors in normal tension glaucoma","volume":"54","author":"Sakata","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bjophthalmol-2018-313375","article-title":"Risk factors for disease progression in low-teens normal-tension glaucoma","volume":"104","author":"Baek","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4103\/ijo.IJO_861_21","article-title":"Significance of non-intraocular pressure (IOP)-related factors particularly in normal tension glaucoma: Looking beyond IOP","volume":"70","author":"Dinakaran","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1111\/aos.12408","article-title":"Circadian intraocular pressure patterns in healthy subjects, primary open angle and normal tension glaucoma patients with a contact lens sensor","volume":"93","author":"Agnifili","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0002-9394(99)80086-5","article-title":"Corneal thickness and curvature in normal-tension glaucoma","volume":"125","author":"Morad","year":"1998","journal-title":"Am. J. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/CM9.0000000000001399","article-title":"Comparison of corneal biomechanics among primary open-angle glaucoma with normal tension or hypertension and controls","volume":"134","author":"Wei","year":"2021","journal-title":"Chin. Med. J. Engl."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2016.04.030","article-title":"New strategies for neuroprotection in glaucoma, a disease that affects the central nervous system","volume":"787","author":"Nucci","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Harada, C., Noro, T., Kimura, A., Guo, X., Namekata, K., Nakano, T., and Harada, T. (2020). Suppression of Oxidative Stress as Potential Therapeutic Approach for Normal Tension Glaucoma. Antioxidants, 9.","DOI":"10.3390\/antiox9090874"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.survophthal.2012.05.003","article-title":"24-hour intraocular pressure and ocular perfusion pressure in glaucoma","volume":"58","author":"Quaranta","year":"2013","journal-title":"Surv. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"308505","DOI":"10.1155\/2015\/308505","article-title":"Ocular Blood Flow and Normal Tension Glaucoma","volume":"2015","author":"Fan","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41598-020-80705-3","article-title":"Nocturnal blood pressure dip and parapapillary choroidal microvasculature dropout in normal-tension glaucoma","volume":"11","author":"Shin","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Konieczka, K., and Flammer, J. (2021). Treatment of Glaucoma Patients with Flammer Syndrome. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184227"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e11377","DOI":"10.1097\/MD.0000000000011377","article-title":"Migraine as a risk factor for primary open angle glaucoma: A systematic review and meta-analysis","volume":"97","author":"Xu","year":"2018","journal-title":"Med. Baltim."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e19468","DOI":"10.1097\/MD.0000000000019468","article-title":"Normal tension glaucoma in obstructive sleep apnea syndrome: A structural and functional study","volume":"99","author":"Chuang","year":"2020","journal-title":"Med. Baltim."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e637","DOI":"10.1111\/aos.12434","article-title":"Metabolic syndrome as a risk factor in normal-tension glaucoma","volume":"92","author":"Kim","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.ajo.2015.09.006","article-title":"Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study","volume":"160","author":"Shim","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0039-6257(05)80073-6","article-title":"Association of endothelin-1 with normal tension glaucoma: Clinical and fundamental studies","volume":"39","author":"Sugiyama","year":"1995","journal-title":"Surv. Ophthalmol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Boccuni, I., and Fairless, R. (2022). Retinal Glutamate Neurotransmission: From Physiology to Pathophysiological Mechanisms of Retinal Ganglion Cell Degeneration. Life, 12.","DOI":"10.3390\/life12050638"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.exer.2009.02.004","article-title":"Neurotrophin roles in retinal ganglion cell survival: Lessons from rat glaucoma models","volume":"88","author":"Johnson","year":"2009","journal-title":"Exp. Eye Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1007\/s10792-021-01959-y","article-title":"Serum and aqueous humor levels of brain-derived neurotrophic factor in patients with primary open-angle glaucoma and normal-tension glaucoma","volume":"41","author":"Cha","year":"2021","journal-title":"Int. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.exer.2018.10.004","article-title":"Investigation of whole mitochondrial genome variation in normal tension glaucoma","volume":"178","author":"Schab","year":"2019","journal-title":"Exp. Eye Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e022987","DOI":"10.1136\/bmjopen-2018-022987","article-title":"Association between normal tension glaucoma and the risk of Alzheimer\u2019s disease: A nationwide population-based cohort study in Taiwan","volume":"8","author":"Chen","year":"2018","journal-title":"BMJ Open"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.survophthal.2012.08.010","article-title":"The role of inflammation in the pathogenesis of glaucoma","volume":"58","author":"Vohra","year":"2013","journal-title":"Surv. Ophthalmol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"100916","DOI":"10.1016\/j.preteyeres.2020.100916","article-title":"Inflammation in Glaucoma: From the back to the front of the eye, and beyond","volume":"83","author":"Baudouin","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejphar.2016.04.031","article-title":"Autoimmune aspects in glaucoma","volume":"787","author":"Bell","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/02713680701375183","article-title":"Antibodies to alpha B-crystallin, vimentin, and heat shock protein 70 in aqueous humor of patients with normal tension glaucoma and IgG antibody patterns against retinal antigen in aqueous humor","volume":"32","author":"Joachim","year":"2007","journal-title":"Curr. Eye Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1111\/aos.13647","article-title":"Impaired cerebrospinal fluid dynamics along the entire optic nerve in normal-tension glaucoma","volume":"96","author":"Pircher","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1167\/iovs.08-2228","article-title":"Intracranial pressure in primary open angle glaucoma, normal tension glaucoma, and ocular hypertension: A case-control study","volume":"49","author":"Berdahl","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ophtha.2006.06.014","article-title":"Relationship of progression of visual field damage to postural changes in intraocular pressure in patients with normal-tension glaucoma","volume":"113","author":"Kiuchi","year":"2006","journal-title":"Ophthalmology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1167\/iovs.17-22093","article-title":"Magnetic Resonance Imaging of Optic Nerve Traction During Adduction in Primary Open-Angle Glaucoma With Normal Intraocular Pressure","volume":"58","author":"Demer","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Murtagh, P., and O\u2019Brien, C. (2022). Corneal Hysteresis, Intraocular Pressure, and Progression of Glaucoma: Time for a \u201cHyst-Oric\u201d Change in Clinical Practice?. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102895"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0021-5155(98)00013-6","article-title":"Effect of trabeculectomy on visual field in progressive normal-tension glaucoma","volume":"42","author":"Daugeliene","year":"1998","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Collaborative Normal-Tension Glaucoma Study Group (1998). The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol., 126, 498\u2013505.","DOI":"10.1016\/S0002-9394(98)00272-4"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.survophthal.2018.07.003","article-title":"Managing normal tension glaucoma by lowering the intraocular pressure","volume":"64","author":"Razeghinejad","year":"2019","journal-title":"Surv. Ophthalmol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0002-9394(03)00478-1","article-title":"Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma","volume":"136","author":"Anderson","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","article-title":"A randomized trial of brimonidine versus timolol in preserving visual function: Results from the Low-Pressure Glaucoma Treatment Study","volume":"151","author":"Krupin","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/S0039-6257(02)00322-3","article-title":"Medical treatment of normal tension glaucoma","volume":"47","author":"Hoyng","year":"2002","journal-title":"Surv. Ophthalmol."},{"key":"ref_72","unstructured":"Islam, S., and Spry, C. (2020). Prostaglandin Analogues for Ophthalmic Use: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet], Canadian Agency for Drugs and Technologies in Health."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kim, J.M., Sung, K.R., Kim, H.K., Park, S.W., Lee, E.J., Jeoung, J.W., Park, H.L., Ahn, J., Yoo, C., and Kim, C.Y. (2021). Long-Term Effectiveness and Safety of Tafluprost, Travoprost, and Latanoprost in Korean Patients with Primary Open-Angle Glaucoma or Normal-Tension Glaucoma: A Multicenter Retrospective Cohort Study (LOTUS Study). J. Clin. Med., 10.","DOI":"10.3390\/jcm10122717"},{"key":"ref_74","first-page":"2566","article-title":"Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension","volume":"41","author":"Orzalesi","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/eye.1999.6","article-title":"The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma","volume":"13","author":"McKibbin","year":"1999","journal-title":"Eye Lond."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.exer.2011.06.022","article-title":"Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction","volume":"93","author":"Yamagishi","year":"2011","journal-title":"Exp. Eye Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41433-019-0671-0","article-title":"New glaucoma medications: Latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost","volume":"34","author":"Mehran","year":"2020","journal-title":"Eye Lond."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/13543776.2019.1665023","article-title":"Adrenergic agonists and antagonists as antiglaucoma agents: A literature and patent review (2013\u20132019)","volume":"29","author":"Nocentini","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/jch.13375","article-title":"Insights on \u03b2-blockers for the treatment of hypertension: A survey of health care practitioners","volume":"20","author":"Egan","year":"2018","journal-title":"J. Clin. Hypertens Greenwich"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00002512-200724060-00007","article-title":"Ocular carteolol: A review of its use in the management of glaucoma and ocular hypertension","volume":"24","author":"Henness","year":"2007","journal-title":"Drugs Aging"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.exer.2007.01.010","article-title":"Vasodilatory mechanism of levobunolol on vascular smooth muscle cells","volume":"84","author":"Dong","year":"2007","journal-title":"Exp. Eye Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.podrm.2020.07.002","article-title":"Betaxolol: A comprehensive profile","volume":"46","author":"Bakheit","year":"2021","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0002-9394(99)00160-9","article-title":"Beta-blocker eyedrops and nocturnal arterial hypotension","volume":"128","author":"Hayreh","year":"1999","journal-title":"Am. J. Ophthalmol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2174\/1871527318666191002095456","article-title":"Carvedilol Promotes Retinal Ganglion Cell Survival Following Optic Nerve Injury via ASK1-p38 MAPK Pathway","volume":"18","author":"Liu","year":"2019","journal-title":"CNS Neurol. Disord Drug Targets"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00417-014-2623-5","article-title":"The influence of new beta-adrenolytics nebivolol and carvedilol on intraocular pressure and iris blood flow in rabbits","volume":"252","author":"Szumny","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Hassan, D.H., Abdelmonem, R., and Abdellatif, M.M. (2018). Formulation and Characterization of Carvedilol Leciplex for Glaucoma Treatment: In-Vitro, Ex-Vivo and In-Vivo Study. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040197"},{"key":"ref_87","first-page":"CR268","article-title":"Effects of the systemic beta-adrenoceptor antagonist nebivolol on ocular hemodynamics in glaucoma patients","volume":"14","author":"Zeitz","year":"2008","journal-title":"Med. Sci. Monit."},{"key":"ref_88","first-page":"94","article-title":"Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma","volume":"76","year":"2020","journal-title":"Cesk Slov. Oftalmol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/14656566.2018.1544241","article-title":"Brimonidine tartrate for the treatment of glaucoma","volume":"20","author":"Oh","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/17512433.2021.1931123","article-title":"Oral acetazolamide for intraocular pressure lowering: Balancing efficacy and safety in ophthalmic practice","volume":"14","author":"Gulati","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bjophthalmol-2021-319530","article-title":"Topical carbonic anhydrase inhibitors and glaucoma in 2021: Where do we stand?","volume":"106","author":"Stoner","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1001\/jamaophthalmol.2016.1881","article-title":"Effect of Pilocarpine Hydrochloride on the Schlemm Canal in Healthy Eyes and Eyes With Open-Angle Glaucoma","volume":"134","author":"Skaat","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0161-6420(92)31782-8","article-title":"Intraocular pressure reduction in normal-tension glaucoma patients","volume":"99","author":"Schulzer","year":"1992","journal-title":"Ophthalmology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1111\/aos.14949","article-title":"Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: The randomized phase II study","volume":"100","author":"Ha","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/mja2.50020","article-title":"Current management of glaucoma","volume":"210","author":"Lusthaus","year":"2019","journal-title":"Med. J. Aust."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Adornetto, A., Rombol\u00e0, L., Morrone, L.A., Nucci, C., Corasaniti, M.T., Bagetta, G., and Russo, R. (2020). Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma. Nutrients, 12.","DOI":"10.3390\/nu12103158"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.survophthal.2021.12.001","article-title":"Nutritional supplementation in the prevention and treatment of glaucoma","volume":"67","author":"Chaudhry","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.survophthal.2021.09.002","article-title":"Non-drug interventions in glaucoma: Putative roles for lifestyle, diet and nutritional supplements","volume":"67","author":"Fahmideh","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4103\/ijo.IJO_2239_21","article-title":"Newer advances in medical management of glaucoma","volume":"70","author":"Mohan","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Sim, R.H., Sirasanagandla, S.R., Das, S., and Teoh, S.L. (2022). Treatment of Glaucoma with Natural Products and Their Mechanism of Action: An Update. Nutrients, 14.","DOI":"10.3390\/nu14030534"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/APO.0000000000000279","article-title":"Ginkgo Biloba Extract in Ophthalmic and Systemic Disease, With a Focus on Normal-Tension Glaucoma","volume":"9","author":"Labkovich","year":"2020","journal-title":"Asia Pac. J. Ophthalmol. Phila"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"136999","DOI":"10.1016\/j.neulet.2022.136999","article-title":"Resveratrol dilates arterioles and protects against N-methyl-d-aspartic acid-induced excitotoxicity in the rat retina","volume":"793","author":"Mori","year":"2023","journal-title":"Neurosci. Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"100767","DOI":"10.1016\/j.preteyeres.2019.06.003","article-title":"Cholinergic nervous system and glaucoma: From basic science to clinical applications","volume":"72","author":"Faiq","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Gandolfi, S., Marchini, G., Caporossi, A., Scuderi, G., Tomasso, L., and Brunoro, A. (2020). Cytidine 5\u2032-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients, 12.","DOI":"10.3390\/nu12030793"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/IJG.0000000000001565","article-title":"Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial","volume":"29","author":"Rossetti","year":"2020","journal-title":"J. Glaucoma"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/1319-4534.301299","article-title":"Coenzyme Q and its role in glaucoma","volume":"34","author":"Ahmad","year":"2020","journal-title":"Saudi J. Ophthalmol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/IJG.0b013e318279b836","article-title":"Effects of coenzyme Q10 in conjunction with vitamin E on retinal-evoked and cortical-evoked responses in patients with open-angle glaucoma","volume":"23","author":"Parisi","year":"2014","journal-title":"J. Glaucoma"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00417-009-1064-z","article-title":"Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: A short-term study by pattern electroretinogram","volume":"247","author":"Falsini","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Nomi, Y., Iwasaki-Kurashige, K., and Matsumoto, H. (2019). Therapeutic Effects of Anthocyanins for Vision and Eye Health. Molecules, 24.","DOI":"10.3390\/molecules24183311"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Passani, A., Posarelli, C., Sframeli, A.T., Perciballi, L., Pellegrini, M., Guidi, G., and Figus, M. (2020). Cannabinoids in Glaucoma Patients: The Never-Ending Story. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123978"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1055\/a-1665-3100","article-title":"Cannabinoids as New Drug Candidates for the Treatment of Glaucoma","volume":"88","author":"Jordan","year":"2022","journal-title":"Planta Med."},{"key":"ref_114","first-page":"430596","article-title":"Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy","volume":"2015","author":"Costagliola","year":"2015","journal-title":"J. Ophthalmol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"10468","DOI":"10.1038\/s41598-020-67527-z","article-title":"Effect of palmitoylethanolamide on inner retinal function in glaucoma: A randomized, single blind, crossover, clinical trial by pattern-electroretinogram","volume":"10","author":"Rossi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2022.05.001","article-title":"Unmet needs in glaucoma therapy: The potential role of hydrogen sulfide and its delivery strategies","volume":"347","author":"Mhatre","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"33950","DOI":"10.1038\/srep33950","article-title":"Caloric restriction promotes cell survival in a mouse model of normal tension glaucoma","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.preteyeres.2010.09.002","article-title":"Use of calcium channel blockers for glaucoma","volume":"30","author":"Araie","year":"2011","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ophtha.2018.06.017","article-title":"Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies","volume":"125","author":"Weinreb","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neulet.2014.12.054","article-title":"Valproic acid prevents retinal degeneration in a murine model of normal tension glaucoma","volume":"588","author":"Kimura","year":"2015","journal-title":"Neurosci. Lett."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e2934","DOI":"10.1038\/cddis.2017.341","article-title":"Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma","volume":"8","author":"Akaiwa","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3349\/ymj.2022.0122","article-title":"Relationship between Androgen Deprivation Therapy and Normal-Tension Glaucoma in Patients with Prostate Cancer: A Nationwide Cohort Study","volume":"63","author":"Ha","year":"2022","journal-title":"Yonsei Med. J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00417-019-04483-z","article-title":"CPAP therapy reduces oxidative stress in patients with glaucoma and OSAS and improves the visual field","volume":"258","author":"Himori","year":"2020","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1111\/aos.13767","article-title":"Long-term rate of progression and target intraocular pressure in patients with normal-tension glaucoma in clinical care","volume":"96","author":"Jensen","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ophtha.2018.12.029","article-title":"Factors Associated with Progression of Japanese Open-Angle Glaucoma with Lower Normal Intraocular Pressure","volume":"126","author":"Sakata","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1167\/iovs.14-16093","article-title":"Progression to Legal Blindness in Patients with Normal Tension Glaucoma: Hospital-Based Study","volume":"56","author":"Sawada","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaophthalmol.2022.1640","article-title":"Long-term Outcomes of Adding Lutein\/Zeaxanthin and \u03c9-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28","volume":"140","author":"Chew","year":"2022","journal-title":"JAMA Ophthalmol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/8\/1172\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:36:08Z","timestamp":1760128568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/8\/1172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":127,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ph16081172"],"URL":"https:\/\/doi.org\/10.3390\/ph16081172","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]}}}